( June 6, 2025, 8:34 AM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court should reject a petition for a writ of certiorari from Purdue Pharma LP and related entities, a generic drug manufacturer told the high court in an opposition brief that argues that Purdue is wrong to suggest that the Federal Circuit U.S. Court of Appeals has created a rigid nexus test when considering evidence of nonobviousness in a dispute over patents controlling Purdue’s Oxycontin drug....